AN2 Therapeutics (ANTX) Receivables - Other (2022 - 2026)
AN2 Therapeutics (ANTX) reported Receivables - Other of $300000.0 for Q1 2026, little changed year-over-year from $300000.0 in Q1 2025, and down 25.0% quarter-over-quarter from $400000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Receivables - Other (2022 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 5 years of Receivables - Other data on file, last reported at $300000.0 in Q1 2026.
- Receivables - Other for Q1 2026 came in at $300000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $300000.0 (changed 0.0% YoY), and the FY2025 annual result was $400000.0, up 33.33% from the prior year.
- Receivables - Other retreated to $300000.0 in Q1 2026 per ANTX's latest filing, from $400000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $500000.0 in Q3 2023 and troughed at $200000.0 in Q4 2022.
- A 5-year average of $328571.4 and a median of $300000.0 in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2023 and 2024: Receivables - Other jumped 100.0% in 2023, then tumbled 40.0% in 2024.
- A 5-year view of Receivables - Other shows it stood at $200000.0 in 2022, then jumped by 100.0% to $400000.0 in 2023, then fell by 25.0% to $300000.0 in 2024, then soared by 33.33% to $400000.0 in 2025, then fell by 25.0% to $300000.0 in 2026.
- Business Quant data shows ANTX's Receivables - Other at $300000.0 in Q1 2026, $400000.0 in Q4 2025, and $400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - |
| 10 | AN2 Therapeutics | 165.87 Mn | 165.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |